The feasibility and cost of neonatal screening for prenatal alcohol exposure by measuring phosphatidylethanol in dried blood spots

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 6, 2013, Pages 1008-1015

  Bakhireva, Ludmila N ^a   Savich, Renate D ^a   Raisch, Dennis W ^a   Cano, Sandra ^a   Annett, Robert D ^a   Leeman, Lawrence ^a   Garg, Mahek ^a   Goff, Chelsea ^a   Savage, Daniel D ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Alcohol; Biomarkers; Guthrie Cards; Newborn Screening; Pregnancy

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; FATTY ACID ESTER; PHOSPHATIDYLETHANOLAMINE;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRIED BLOOD SPOT TESTING; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MECONIUM; NEWBORN; NEWBORN SCREENING; PRENATAL EXPOSURE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ALCOHOL DRINKING; ALCOHOL-INDUCED DISORDERS; BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, LIQUID; FEASIBILITY STUDIES; FEMALE; FETAL ALCOHOL SPECTRUM DISORDERS; GLYCEROPHOSPHOLIPIDS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TANDEM MASS SPECTROMETRY;

EID: 84878380379     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12045     Document Type: Article

References (51)

1. American Academy of Pediatrics (2000) Fetal alcohol syndrome and alcohol-related neurodevelopmental disorders. Pediatrics 106:358-361.
2. American College of Obstetricians and Gynecologists (2008) ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obstet Gynecol 112:1449-1460.
3. Anderson JE, Ebrahim S, Floyd L, Atrash H (2006) Prevalence of risk factors for adverse pregnancy outcomes during pregnancy and the preconception period-United States, 2002-2004. Matern Child Health J 10:S101-S106.
4. Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C (2006) Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol 41:431-437.
5. Aradottir S, Seidl S, Wurst FM, Jonsson BA, Alling C (2004) Phosphatidylethanol in human organs and blood: a study on autopsy material and influences by storage conditions. Alcohol Clin Exp Res 28:1718-1723.
6. Astley SJ, Bailey D, Talbot C, Clarren SK (2000) Fetal alcohol syndrome (FAS) primary prevention through FAS diagnosis: I. Identification of high-risk birth mothers through the diagnosis of their children. Alcohol Alcohol 35:499-508.
7. Bakhireva L, Cano S, Rayburn WF, Savich R, Leeman L, Anton RF, Savage D (2012a) Advanced gestational age increases serum carbohydrate-deficient transferrin levels in abstinent pregnant women. Alcohol Alcohol 47:683-687.
8. Bakhireva L, Savich R, Cano S, Goff C, Annett R, Rayburn W, Savage D (2012b) Validity and feasibility of neonatal screening for prenatal alcohol exposure by measuring phosphatidylethanol in dried blood spots of a newborn. Alcohol Clin Exp Res Suppl 36:43A (abstract 0129).
9. Center for Disease Control and Prevention (2009) Alcohol use among pregnant and nonpregnant women of childbearing age - United States, 1991-2005. MMWR Morb Mortal Wkly Rep 58:529-532.
10. Clinical and Laboratory Standards Institute (2007) Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard. 5th ed. CLSI publication LA4-A5, in Series Blood collection on filter paper for newborn screening programs; approved standard. 5th ed. CLSI publication LA4-A5, Vol. 27. CLSI, Wayne, PA.
11. Comasco E, Nordquist N, Leppert J, Oreland L, Kronstrand R, Alling C, Nilsson KW (2009) Adolescent alcohol consumption: biomarkers PEth and FAEE in relation to interview and questionnaire data. J Stud Alcohol Drugs 70:797-804.
12. Faller A, Richter B, Kluge M, Koenig P, Seitz HK, Thierauf A, Gnann H, Winkler M, Mattern R, Skopp G (2011) LC-MS/MS analysis of phosphatidylethanol in dried blood spots versus conventional blood specimens. Anal Bioanal Chem 401:1163-1166.
13. Farst KJ, Valentine JL, Hall RW (2011) Drug testing for newborn exposure to illicit substances in pregnancy: pitfalls and pearls. Int J Pediatr 2011:951616.
14. Gifford AE, Farkas KJ, Jackson LW, Molteno CD, Jacobson JL, Jacobson SW, Bearer CF (2010) Assessment of benefits of a universal screen for maternal alcohol use during pregnancy. Birth Defects Res A Clin Mol Teratol 88:838-846.
15. Gnann H, Weinmann W, Thierauf A (2012) Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. Alcohol Clin Exp Res 36:1507-1511.
16. Goh YI, Hutson JR, Lum L, Roukema H, Gareri J, Lynn H, Koren G (2010) Rates of fetal alcohol exposure among newborns in a high-risk obstetric unit. Alcohol 44:629-634.
17. Gray T, Huestis M (2007) Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem 388:1455-1465.
18. Halmesmaki E, Roine R, Salaspuro M (1992) Gamma-glutamyltransferase, aspartate and alanine aminotransferases and their ratio, mean cell volume and urinary dolichol in pregnant alcohol abusers. Br J Obstet Gynaecol 99:287-291.
19. Handmaker NS, Rayburn WF, Meng C, Bell JB, Rayburn BB, Rappaport VJ (2006) Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures. Alcohol Clin Exp Res 30:892-898.
20. Hannuksela ML, Liisanantti MK, Nissinen AE, Savolainen MJ (2007) Biochemical markers of alcoholism. Clin Chem Lab Med 45:953-961.
21. Harrison KL (1979) Fetal erythrocyte lifespan. Aust Paediatr J 15:96-97.
22. Hartmann S, Aradottir S, Graf M, Wiesbeck G, Lesch O, Ramskogler K, Wolfersdorf M, Alling C, Wurst FM (2007) Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol 12:81-84.
23. Helander A, Peter O, Zheng Y (2012) Monitoring of the alcohol biomarkers PEth, CDT and EtG/EtS in an outpatient treatment setting. Alcohol Alcohol 47:552-557.
24. Helander A, Zheng Y (2009) Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. Clin Chem 55:1395-1405.
25. Hopkins RB, Paradis J, Roshankar T, Bowen J, Tarride JE, Blackhouse G, Lim M, O'Reilly D, Goeree R, Longo CJ (2008) Universal or targeted screening for fetal alcohol exposure: a cost-effectiveness analysis. J Stud Alcohol Drugs 69:510-519.
26. Hudak ML, Tan RC (2012) Neonatal drug withdrawal. Pediatrics 129:e540-e560.
27. Isaksson A, Walther L, Hansson T, Andersson A, Alling C (2011) Phosphatidylethanol in blood (B-PEth): a marker for alcohol use and abuse. Drug Test Anal 3:195-200.
28. Jones J, Jones M, Plate C, Lewis D (2011) The detection of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol in human dried blood spots. Anal Methods 3:1101-1106.
29. Jones KL, Robinson LK, Bakhireva LN, Marintcheva G, Storojev V, Strahova A, Sergeevskaya S, Budantseva S, Mattson SN, Riley EP, Chambers CD (2006) Accuracy of the diagnosis of physical features of fetal alcohol syndrome by pediatricians after specialized training. Pediatrics 118:e1734-e1738.
30. Kenan N, Larsson A, Axelsson O, Helander A (2011) Changes in transferrin glycosylation during pregnancy may lead to false-positive carbohydrate-deficient transferrin (CDT) results in testing for riskful alcohol consumption. Clin Chim Acta 412:129-133.
31. Kwong TC, Ryan RM (1997) Detection of intrauterine illicit drug exposure by newborn drug testing. National Academy of Clinical Biochemistry. Clin Chem 43:235-242.
32. Littner Y, Bearer CF (2007) Detection of alcohol consumption during pregnancy-current and future biomarkers. Neurosci Biobehav Rev 31:261-269.
33. Lupton C, Burd L, Harwood R (2004) Cost of fetal alcohol spectrum disorders. Am J Med Genet C Semin Med Genet 127C:42-50.
34. Marcellus L (2007) Is meconium screening appropriate for universal use? Science and ethics say no. Adv Neonatal Care 7:207-214.
35. McDade TW, Williams S, Snodgrass JJ (2007) What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography 44:899-925.
36. Moore C, Jones J, Lewis D, Buchi K (2003) Prevalence of fatty acid ethyl esters in meconium specimens. Clin Chem 49:133-136.
37. New Mexico Department of Health (2011) The state of health in New Mexico. Available at: http://nmhealth.org/CommunicationsOffice/2010%20News%20Releases/SoH%202011%20for%20download%20FINAL.pdf. Accessed July 15, 2012.
38. Ostrea EM Jr, Brady M, Gause S, Raymundo AL, Stevens M (1992) Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics 89:107-113.
39. Paley B, O'Connor MJ (2009) Intervention for individuals with fetal alcohol spectrum disorders: treatment approaches and case management. Dev Disabil Res Rev 15:258-267.
40. Sarkola T, Eriksson CJ, Niemela O, Sillanaukee P, Halmesmaki E (2000) Mean cell volume and gamma-glutamyl transferase are superior to carbohydrate-deficient transferrin and hemoglobin-acetaldehyde adducts in the follow-up of pregnant women with alcohol abuse. Acta Obstet Gynecol Scand 79:359-366.
41. Steward S, Law T, Randall P, Newman R (2010) Phosphatidylethanol and alcohol consumption in reproductive age women. Alcohol Clin Exp Res 34:488-492.
42. Stewart SH, Reuben A, Brzezinski WA, Koch DG, Basile J, Randall PK, Miller PM (2009) Preliminary evaluation of phosphatidylethanol and alcohol consumption in patients with liver disease and hypertension. Alcohol Alcohol 44:464-467.
43. Streissguth AP, Bookstein FL, Barr HM, Sampson PD, O'Malley K, Young JK (2004) Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J Dev Behav Pediatr 25:228-238.
44. Swarnam K, Soraisham AS, Sivanandan S (2012) Advances in the management of meconium aspiration syndrome. Int J Pediatr 2012:359571.
45. Taylor M (2009) What is sensitivity analysis? Hayward Medical Communications, Hayward Group Ltd. Available at: http://www.whatisseries.co.uk/whatis/. Accessed July 30, 2012.
46. Varga A, Alling C (2002) Formation of phosphatidylethanol in vitro in red blood cells from healthy volunteers and chronic alcoholics. J Lab Clin Med 140:79-83.
47. Varga A, Hansson P, Johnson G, Alling C (2000) Normalization rate and cellular localization of phosphatidylethanol in whole blood from chronic alcoholics. Clin Chim Acta 299:141-150.
48. Wallman CM, Smith PB, Moore K (2011) Implementing a perinatal substance abuse screening tool. Adv Neonatal Care 11:255-267.
49. Wurst FM, Thon N, Aradottir S, Hartmann S, Wiesbeck GA, Lesch O, Skala K, Wolfersdorf M, Weinmann W, Alling C (2010) Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self-reports. Addict Biol 15:88-95.
50. Zelner I, Hutson JR, Kapur BM, Feig DS, Koren G (2012a) False-positive meconium test results for fatty acid ethyl esters secondary to delayed sample collection. Alcohol Clin Exp Res 36:1497-1506.
51. Zelner I, Shor S, Lynn H, Roukema H, Lum L, Eisinga K, Koren G (2012b) Neonatal screening for prenatal alcohol exposure: assessment of voluntary maternal participation in an open meconium screening program. Alcohol 46:269-276.